CoChat

Src Continues Aging: Current and Future Clinical Directions

Kopetz, Scott, Shah, Ami N., Gallick, Gary E. · 2007 · Clinical Cancer Research

Published version of a preprint

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Aberrant activation of members of the Src family of nonreceptor protein tyrosine kinases is common in solid tumor malignancies and may contribute to the development and/or progression of these tumors. As a result, four Src inhibitors are now in more than 50 clinical trials for at least 14 different types of solid tumors. In this review, we briefly discuss the preclinical rationale for Src inhibitors, the development strategies most likely to be successful in the clinic, and the rationale for Src inhibitors in combination with other agents as part of a more comprehensive therapeutic strategy. As the use of Src family inhibitors in clinical trials on solid tumors is in its infancy, further studies on the roles of Src family kinases in tumor progression, chemoresistance, epidermal-to-mesenchymal transition, and other properties of tumor progression will be important in designing the most effective clinical trials using these inhibitors.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-07-1902

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 54 references

Research works printed but not linked: 6

  1. Desgrosellier J, Prevost N, Barnes L, Shattil S, Cheresh D. Disruption of an integrin αvβ3/c-src complex inhibits αvβ3-mediated tumor progression and metastasis. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007, Los Angeles, California. p. 2186.
  2. Verbeek BS, Vroom TM, Adriaansen-Slot SS, et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996;180:383–8. · DOI · Paper page
  3. Park SI, Gallick GE. c-Src activation in the tumor-associated endothelial cells contributes to the lymph node metastases of prostate cancer cells. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007, Los Angeles, California. p. 3002.
  4. Zhang J, Kalyankrishna S, Wislez M, et al. Src-Family Kinases are activated in non-small cell lung cancer and promote the survival of EGFR-dependent cell lines. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007, Los Angeles, California. p. 2064.
  5. Kopetz S, Wu J, Davies M, et al. Synergistic activity of Src and EGFR inhibitors in colon cancer. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007, Los Angeles, California p. 4079.
  6. Nakagawa T, Tanaka S, Suzuki H, et al. Overexpression of the csk gene suppresses tumor metastasis in vivo. Int J Cancer 2000;88:384–91. · doi:10.1002/1097-0215(20001101)88:3<384::aid-ijc10>3.0.co;2-b · Paper page

Cited by

See all 113

Metadata

Authors
Kopetz, S., Shah, A. N., & Gallick, G. E.
Affiliations
  • 1Gastrointestinal Medical Oncology, Departments of
  • The University of Texas MD Anderson Cancer Center (US)
  • 2Cancer Biology, and
Venue
Clinical Cancer Research
Published
2007-12-15
Volume
13
Issue
24
Pages
7232-7236
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2171629680
Cited by
111
References
54
Citations by year
2025: 1 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 8 · 2015: 4 · 2014: 6 · 2013: 10 · 2012: 12
FWCI
1.43
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5p20ca101936-05)
  • National Cancer Institute (5 P20 CA101936, U54CA090810, T-32 CA 09599, T32CA009599, K12CA088084)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
Src family kinases, Src kinase inhibitor, non-receptor tyrosine kinase, solid tumors, tumor progression, chemoresistance, combination therapy, clinical trials, kinase inhibitors
MeSH terms
Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Enzyme Inhibitors, Humans, Neoplasms, src-Family Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Src Continues Aging: Current and Future Clinical Directions. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-1902
The paper
Kopetz, S., Shah, A. N., & Gallick, G. E. (2007). Src Continues Aging: Current and Future Clinical Directions. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-1902

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.